Table 1.
Demographics and Clinical Characteristics of Patients Included (N = 233)
| Demographics | N (%) |
|---|---|
| Gender (female)—N (%) | 111 (47.8) |
| Age (years) mean (SD) | 54.4 (12.7) |
| Race | |
| Caucasian—N (%) | 133 (57.3) |
| Latin—N (%) | 89 (38.4) |
| Arab—N (%) | 6 (2.3) |
| Past medical history | N (%) |
| Hypertension—N (%) | 57 (24.5) |
| Dyslipidemia—N (%) | 53 (22.7) |
| Diabetes Mellitus—N (%) | 30 (3.3) |
| Obesity—N (%) | 54 (23.2) |
| Smoking habit—N (%) | 17 (7.3) |
| Cardiovascular disease—N (%) | 7 (3.0) |
| Pulmonary disease—N (%) | 34 (14.6) |
| Previous Thromboembolic Disease—N (%) | 2 (0.9) |
| Familiar Thromboembolic Disease—N (%) | 6 (2.6) |
| Malignancy—N (%) | 3 (1.3) |
| Systemic Autoimmune Disease—N (%) | 4 (1.7) |
| Phyisical exam | |
| SBP (mmHg) mean (SD) | 121.7 (18.0) |
| Heart rate (bpm) mean (SD) | 84.6 (14.2) |
| Temperature (°C) mean (SD) | 36.8 (0.7) |
| SO2 (%) mean (SD) | 95.6 (1.6) |
| Respiratory rate (rpm) mean (SD) | 19.1 (4.0) |
| Weight (kg) mean (SD) | 81.1 (16.7) |
| Height (cm) mean (SD) | 166.2 (10.1) |
| Oxygen (lpm) mean (SD) | 1.6 (2.7) |
| Laboratory results—Mean (SD) | |
| WBC × 109/L (SD) | 6.2 (2.7) |
| Lymphocite × 109/L (SD) | 1.1 (0.6) |
| Platelets × 109/L (SD) | 224.1 (100.8) |
| Creatinine—mg/dL (SD) | 1.11 (4.4) |
| AST—U/L (SD) | 53.7 (38.6) |
| Total bilirrubin—mg/dL (SD) | 0.7 (0.4) |
| LDH—U/L (SD) | 368.3 (322.4) |
| CK—U/L (SD) | 180.1 (256.3) |
| D‐dimer—ng/mL (SD) | 729.7 (1182.6) |
| D‐dimer at 1 week from admission—ng/mL (SD) | 1723.6 (9378.8) |
| PCT—ng/mL (SD) | 0.1 (0.1) |
| C‐Reactive Protein—mg/dL (SD) | 66.0 (63.7) |
| IL‐6—pg/mL (SD) | 152.3 (314.3) |
| Imaging modalities | 89 (92.7) |
| Chest X‐ray—Normal—N (%) | 5 (2.1) |
| Chest X‐ray—Infiltrates—N (%) | 228 (97.9) |
| Chest X‐ray—Involvement >50%—N (%) | 141 (65.6) |
| Duplex Ultrasound—DVT—N (%) | 1 (0.4) |
| Number of Duplex Ultrasound performed during follow‐up | 3 (1.3) |
| 0—N (%) | |
| 1—N (%) | 147 (63.1) |
| 2—N (%) | 64 (27.5) |
| 3—N (%) | 13 (5.6) |
| 4—N (%) | 2 (0.9) |
| 5 or more—N (%) | 4 (1.7) |
| Computed Tomography Angiography—PE—N (%) | 2 (0.9) |
| Therapy | |
| Remdesivir—N (%) | 8 (3.4) |
| Antibiotics—N (%) | 28 (12.3) |
| Tocilizumab—N (%) | 7 (3.0) |
| Dexamethasone 6 mg—N (%) | 175 (75.1) |
| Dexamethasone 20 mg—N (%) | 38 (16.3) |
| Low molecular weight heparin | |
| Prophylactic dose | 196 (84.1) |
| Intermediate dose | 24 (10.3) |
| Anticoagulation dose | 6 (2.6) |
| Oxygen—N (%) | |
| Nasal Cannula to Non‐rebreather mask—N (%) | 100 (53.2) |
| High flow nasal cannula or non‐invasive ventilation—N (%) | 23 (12.2) |
| Mechanical ventilation—N (%) | 7 (3.7) |
| Follow‐up | |
| Admission to an Intermediate Respiratory Care Unit or Intensive Care Unit—N (%) | 32 (13.9) |
| Mortality—N (%) | 3 (1.3) |
| Length of stay—N of days (SD) | 7.1 (34.3) |
| Complications at 1 month—N (%) | 2 (0.9) |
| DVT or PE diagnosis at 1 month from hospital discharge—N (%) | 0 (0.0) |
CK, creatine kinase; DVT, deep vein thrombosis; IL‐6, Interleukin 6; LDH, lactate dehydrogenase; N, number; PCT, procalcitonin; PE, pulmonary embolism; SBP, systolic blood pressure; SD, standard deviation.